Member Info for BuenaVista

Me: please provide sources for that

ChatGPT4: For the most accurate and detailed information about the partnership between Avacta and Novartis, you can refer to:

Official Press Releases: Both companies often issue press releases that outline the details of their collaborations. You can find these on their respective websites in the news or investor relations sections.

Financial News Websites: Platforms like Bloomberg, Reuters, or BioSpace frequently report on pharmaceutical partnerships and may have articles discussing this specific collaboration.

Scientific Journals: Occasionally, collaborations will be discussed in journals that publish research related to the therapeutic areas they are focusing on.

Regulatory Filings: If either company is publicly traded, their filings with regulatory bodies like the SEC (in the U.S.) can provide detailed information about significant partnerships.

Industry Reports: Market research firms may publish analyses that include discussions of partnerships in the biotech and pharmaceutical industries.

You can search these sources for the most current and comprehensive information regarding the Avacta and Novartis partnership.

It was very tedious, but this is how it went...

Me: What's the partnership relationship between avacta and novartis?

Chat GPT4: Avacta and Novartis have entered into a partnership focused on developing innovative therapeutics, particularly in the field of cancer treatment. The collaboration leverages Avacta's Affimer technology, which is designed to create highly specific and effective drugs.

This partnership aims to combine Avacta's novel drug modalities with Novartis's extensive resources and expertise in drug development and commercialization. Together, they seek to enhance the efficacy of treatments and potentially accelerate the path to market for new therapies.

If you're looking for specific details about the partnership, such as financial terms or project timelines, I can provide general insights, but specific numbers might not be publicly available.

Hallelujah! Praise be! The Nation is saved! All hail Avacta, the Lady of the Tamp! Light the blue touch paper and 🚀

Great! Now how about the relationship between Avacta and Prince Charming?

Thanks for the ChatGPT[4] heads up btw.

Maybe ask ChatGPT about partnerships between AstraZeneca and Affibody Medical AB. The ChatGPT I can access only goes up until September 2021 and is limited in the numner of words it produces.

Sorry to hear of your mum's passing yuyus.

Maybe just take the advice in the first part of my response then: https://www.lse.co.uk/rns/AVCT/ and look for the 'Issue of Equity and Total Voting Rights' RNSes.

I enjoyed your children's fairy story about Avacta and Daiichi Sankyo. Can you now do one about Avacta and AstraZeneca please?

@Blownitalready, I recommend you switch back to Google Assistant or just don't ask it questions as it gets sidetracked too easily. AZ has a partnership with Swedish company Affibody Medical AB and their proprietary Affibody® scaffold proteins, similar to but not the same as Avacta's Affimer® scaffold proteins. There is no agreement between AZ and Avacta. Sources: https://www.google.com/search?q=%22affibody%22+%22astrazeneca%22 https://www.google.com/search?q=%22avacta%22+%22astrazeneca%22

Interesting fact(s): Astra was a Swedish company that merged with Zeneca, the pharma business split off from ICI.

Lol. Two twatters not open to a critical discussion and something from the Bbc (ffs!)

Unless there is a licence/partnership deal Dx WILL be a distressed sale.

And now I leave the floor to 'Windy', bless his little cotton socks, and his fluffer.

8 recs 🤣🤣🤣

Follow Charles Latan. He'll make you rich!🤣🤣🤣

If it is npow just an Avacta dodo, it's a pity they can't license it out to some company for £5 (undisclosed) with milestone payments and 10% royalties on sales.

Well that went well. Greedy c***s.

You say that Timster but, along with the 21 folk twits, I'll wait for Charles LaTan's pronouncement on the Bagel Broadcasting Corp before making my trading, oops!, sorry I meant investment, decision.

HurstBot's 21 recs must be delighted that we're powering through the 70-80 level as they slap themselves on the back for having followed his tip and buying at 68.5p.

Or, even at this Phase 1a stage, it was clear that there is only one realistically viable STS indication/market so to include a second STS indication would just be a waste of money.

Pity we can't ask questions about CC's strategy on the 30th or any time other than the AGM.

But anyway, good Phase 1b data for TNBC should produce a deal for AVA6000 if anything is going to.

HurstBot is many things to many people. Unruly to the programmers but a guru to the 21 wise folks who upticked "we will comfortable making our way through the 70-80 level before the end of the week." I'll bet they want to Make America Great Again as well - if they think it'll make them rich.

As recently as 30 September, Avacta were stating, in the Interims RNS: "Enrollment in the recommended dose for expansion (RDE) cohort is ongoing, focusing on patients with high-grade sarcomas and a subset of head and neck cancer (salivary gland cancer)" https://www.lse.co.uk/rns/AVCT/interim-results-ioqtbnn2n67c3yh.html

So something must have happened between then and Wednesday. I'd suggest discussions with ??? had sufficiently progressed for Avacta to either be including TNBC for a pharma company that will commit to funding Phase 2 TNBC pending Phase 1b efficacy data meeting certain requirements OR Avacta decided that a second STS indication would just be a second small market and are going for TNBC in the hope of sealing a deal with one of the interested but as yet uncommitted pharma companies.

@JL, 100% Avacta are looking for a partner or licensee for AVA6000 Phase 2 studies for breast cancer and good Phase 1b efficacy data would be the key to unlock already expressed commitment or interest. What commitment and/or level(s) of interest there are and when sufficient decisive data will be available we can only speculate.

Https://www.bbc.co.uk/news/articles/c7v6g9q6rjqo